List of Excipients in Branded Drug SEIZALAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Meridian Medical Technologies LLC	SEIZALAM	midazolam hydrochloride	11704-650	BENZYL ALCOHOL
Meridian Medical Technologies LLC	SEIZALAM	midazolam hydrochloride	11704-650	EDETATE DISODIUM
Meridian Medical Technologies LLC	SEIZALAM	midazolam hydrochloride	11704-650	HYDROCHLORIC ACID

Seizalam Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 5, 2026

Seizalam is a 10 mg/2 mL intramuscular midazolam hydrochloride injection approved by the FDA for the treatment of status epilepticus in adults. Its formulation uses a deliberately narrow excipient system: sodium chloride, hydrochloric acid, sodium hydroxide, and water for injection. The product’s commercial opportunity is concentrated in emergency-use presentation, device integration, supply reliability, and lifecycle management rather than in a complex excipient patent estate.[1]

The formulation strategy is technically sound. Midazolam has limited aqueous solubility at near-neutral pH, while acidic conditions improve solubility. Seizalam therefore uses an acidic, preservative-free aqueous formulation supplied in a single-dose vial. The principal opportunity is to preserve that formulation’s rapid intramuscular performance while improving administration speed, dose accuracy, packaging, and field usability.

What is Seizalam and how is it formulated?

Seizalam is a midazolam injection indicated for the treatment of status epilepticus in adults. Each 2 mL single-dose vial contains 10 mg of midazolam, equivalent to 5 mg/mL of midazolam hydrochloride.[1]

Seizalam composition

Component	Function
Midazolam hydrochloride	Active pharmaceutical ingredient
Sodium chloride	Tonicity adjustment
Hydrochloric acid	pH adjustment and maintenance of midazolam solubility
Sodium hydroxide	Final pH adjustment
Water for injection	Vehicle

The formulation is preservative-free and intended for intramuscular administration. The label specifies a pH range of approximately 2.9 to 3.7.[1] The acidic environment is central to the product’s physical stability because midazolam becomes less soluble as the formulation approaches physiological pH.

Why does Seizalam use an acidic formulation?

Midazolam contains a benzodiazepine ring system with pH-dependent solubility. In an acidic solution, the molecule is more protonated and remains water soluble. At higher pH, the compound can convert toward a less soluble form, creating precipitation risk.

The formulation therefore avoids unnecessary buffering near physiological pH. Hydrochloric acid and sodium hydroxide provide pH control without introducing a more complex buffer system that could affect compatibility, osmolality, stability, or injection tolerability.

The strategy has four commercial advantages:

1. It uses few excipients.
2. It reduces formulation complexity.
3. It avoids preservative exposure in an emergency injectable.
4. It supports a compact, ready-to-administer presentation.

The principal technical tradeoff is local injection tolerability from the acidic solution. Any reformulation that moves the product toward neutral pH would need to address midazolam precipitation, chemical stability, syringe compatibility, and local tissue tolerance.

What excipients are protected by Seizalam’s formulation?

No standalone excipient is the principal source of Seizalam’s differentiation. Sodium chloride, hydrochloric acid, sodium hydroxide, and water for injection are established pharmaceutical excipients with broad prior use.

The potential value lies in the combination of:

• Midazolam hydrochloride at a defined concentration
• An acidic pH window
• A preservative-free single-dose presentation
• Intramuscular delivery
• Packaging and administration instructions for emergency seizure treatment

A formulation claim covering a particular pH range, concentration, excipient ratio, stability profile, or container configuration could create protection if supported by valid patent claims. That protection would depend on claim scope, priority dates, prosecution history, terminal disclaimers, and patent listing status.

The commercial strength of such claims would generally be lower than that of claims covering a novel active ingredient or complex delivery platform. Competitors could attempt design-around strategies involving:

• A different pH range
• A different salt form
• A prefilled syringe or autoinjector
• A different concentration
• A nasal, buccal, or other non-intramuscular route
• An alternative stabilizer or buffer system
• A different container closure or device

What is the FDA regulatory status of Seizalam?

Seizalam was approved by the FDA in May 2018 under New Drug Application 211321.[2] The product is an emergency-use intramuscular formulation of midazolam, an established active ingredient with extensive prior clinical use.

Regulatory item	Seizalam status
Active ingredient	Midazolam hydrochloride
Dosage form	Injection
Route	Intramuscular
Strength	5 mg/mL
Presentation	10 mg/2 mL single-dose vial
FDA approval	May 2018
NDA	211321
Primary indication	Status epilepticus in adults
Controlled substance	Schedule IV benzodiazepine
Preservatives	None identified in the labeled composition

Seizalam’s regulatory value comes from its specific clinical and administration profile. The FDA approval established an intramuscular product intended for rapid seizure treatment when intravenous access is delayed or unavailable.[1,2]

When does Seizalam lose exclusivity?

Seizalam’s active ingredient is not new. Midazolam has been marketed for decades, and basic midazolam composition and use claims are expected to face extensive prior-art pressure.

The key exclusivity categories are different:

Exclusivity category	Likely commercial relevance
New chemical entity exclusivity	Not applicable to midazolam
Orphan-drug exclusivity	Must be assessed against the specific approved indication and FDA designation record
Pediatric exclusivity	Possible only if separately granted
New clinical investigation exclusivity	May apply if statutory requirements were met
Formulation patents	Potentially relevant if valid and listed
Device patents	Potentially relevant to autoinjector or prefilled presentations
Method-of-use patents	Potentially relevant to status epilepticus treatment

The FDA Orange Book must be checked for current patent listings and regulatory exclusivity. A definitive patent-expiration date cannot be assigned solely from the approval date. The original Seizalam NDA, the product label, and the FDA Orange Book are the controlling sources for listed patents and exclusivity data.[1,3]

Because the active ingredient is old, generic or follow-on competition can arise through an abbreviated pathway if a competing product satisfies applicable FDA requirements. The main barriers are likely to involve product sameness, injection performance, labeling, supply reliability, and any enforceable formulation or device claims.

How many patents cover Seizalam?

The number of patents covering Seizalam depends on the relevant definition:

• Patents listed in the Orange Book for NDA 211321
• Patents owned or licensed by the sponsor but not listed
• Patents covering midazolam formulations generally
• Patents covering emergency seizure treatment methods
• Patents covering packaging, autoinjectors, or administration systems

These categories should not be treated as equivalent. Orange Book listing affects certain ANDA patent-certification procedures, while unlisted patents may still support separate patent litigation or licensing strategies.

Seizalam’s core formulation is relatively simple. That limits the likely breadth of composition-of-matter protection. The strongest potential protection would more likely come from a narrowly defined formulation, a particular delivery device, or a validated clinical use with non-obvious technical advantages.

What generic entry risks exist for Seizalam?

Generic entry risk is material because midazolam is a well-known active ingredient and the product does not depend on a sophisticated biologic, nanoparticle, or controlled-release platform.

Generic pathways

A competing injectable product could pursue:

• An ANDA, if the product can establish pharmaceutical equivalence and bioequivalence or an applicable waiver
• A 505(b)(2) application, if the sponsor relies on published data while introducing a different formulation, route, device, or clinical use
• A conventional NDA for a materially different rescue product

The likely competitive focus is not only the drug substance. It includes:

• Concentration
• Vial fill volume
• pH
• Sterility assurance
• Container closure
• Extractables and leachables
• Injection-site tolerability
• Shelf life
• Labeling for emergency administration
• Distribution to hospitals, ambulances, military users, and emergency departments

Paragraph IV challenge exposure

A Paragraph IV challenge would be relevant if the Orange Book contains unexpired patents for NDA 211321. The challenger would need to certify that a listed patent is invalid, unenforceable, or not infringed, or that the proposed product does not require the patented subject matter.

The risk profile would be stronger for a generic if:

• No blocking Orange Book patents remain;
• the reference product has no exclusive regulatory protection;
• the generic can match the formulation and presentation;
• the sponsor cannot establish a meaningful difference in clinical performance; and
• the market has sufficient volume to justify injectable development and manufacturing.

A formulation patent that claims only a narrow pH or excipient combination may be vulnerable to invalidity or design-around arguments, depending on the specification and prior art.

What formulation patents could protect a Seizalam follow-on product?

The most commercially useful formulation patent opportunities would involve a measurable technical improvement rather than a simple substitution of one conventional excipient for another.

Potential formulation claim areas

Improved pH and precipitation control

A formulation could seek to maintain midazolam solubility while reducing the acidity of the injection. The claim would need to connect the excipient system to a demonstrated technical result, such as:

• Reduced precipitation after dilution
• Improved stability during storage
• Lower injection-site irritation
• Better compatibility with polymeric syringes
• Reduced degradation products

Ready-to-use prefilled syringe

A prefilled syringe could reduce preparation time and dose-transfer errors. Patentable subject matter could include the combination of:

• A specific midazolam concentration
• A defined internal syringe surface
• A low-sorption closure
• A controlled headspace
• A stability period
• A tamper-evident emergency presentation

Autoinjector formulation

An autoinjector may require a formulation with controlled viscosity, reliable delivery force, and compatibility with the device’s needle and reservoir. The strongest claims would likely combine formulation and device parameters.

Stability-enhanced presentations

Potential innovations include improved resistance to:

• Heat exposure
• Freeze-thaw cycling
• Light
• Container interaction
• Agitation during transport
• Long-term storage in emergency kits

An actual patent position would require evidence that the proposed excipient system produces a non-obvious advantage over the labeled formulation and known midazolam injections.

What commercial opportunities exist for Seizalam excipients?

The most attractive excipient opportunities are those that support a product upgrade without compromising the acidic solubilization principle.

1. Low-irritancy acidic systems

A reformulated product could seek to reduce local tissue irritation while maintaining midazolam solubility. Candidate approaches may involve controlled pH, alternative counterions, or carefully selected buffering systems. These approaches require compatibility and precipitation studies because a modest pH shift can materially change solubility.

2. Prefilled emergency presentations

A prefilled syringe can reduce the number of preparation steps in ambulances, emergency departments, military settings, and seizure rescue kits. The excipient value would be linked to long-term stability in the final container rather than to a novel inactive ingredient alone.

3. Autoinjector-compatible formulations

A device-based presentation could create a higher-value product with greater differentiation from vial-based generics. Key development requirements include injection force, dose accuracy, needle performance, device temperature range, and container closure integrity.

4. Heat-stable emergency stock

Emergency products may be stored in ambulances, emergency bags, field hospitals, and other locations where temperature control is imperfect. A formulation or package that extends usable storage under temperature excursions could support institutional purchasing and lifecycle patents.

5. Alternative rescue routes

Nasal midazolam products already compete in seizure rescue, including Nayzilam. An intramuscular product remains differentiated for professional emergency use, but nasal delivery has advantages in home and caregiver settings. The strongest commercial strategy may be portfolio coverage across:

• Intramuscular emergency injection
• Intranasal rescue
• Buccal or sublingual delivery
• Autoinjector administration

Each route creates a distinct formulation and device opportunity.

How does Seizalam compare with other midazolam rescue products?

Product type	Administration	Primary user	Formulation opportunity	Competitive position
Seizalam	Intramuscular injection	Clinicians and emergency responders	pH control, prefilled syringe, autoinjector	Rapid professional rescue
Conventional midazolam injection	Intravenous or intramuscular	Healthcare professionals	Low-cost generic supply	Broad hospital use
Nayzilam	Intranasal spray	Caregivers and patients	Mucoadhesion, spray performance, stability	Noninvasive outpatient rescue
Diazepam rectal gel	Rectal	Caregivers	Gel viscosity and applicator design	Established home rescue
Generic injectable benzodiazepines	Various	Hospitals and emergency services	Cost, supply, packaging	Price-driven competition

Seizalam’s principal differentiation is the combination of a high-dose intramuscular presentation and an FDA-approved status epilepticus indication. Its weakness is that the underlying active ingredient and basic injectable technology are mature.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are practical rather than scientifically extreme. A competitor must establish:

• Sterile compounding and aseptic filling
• Reliable pH control
• Low particulate levels
• Container closure integrity
• Chemical stability
• Consistent fill volume
• Compatibility with glass vials, syringes, or autoinjectors
• Controlled-substance handling and distribution
• Commercial-scale supply reliability

Midazolam manufacturing is established, but sterile injectable capacity is constrained relative to ordinary oral solid-dose manufacturing. Shortages, contract-manufacturing limitations, and regulatory observations can affect market entry more than the excipient cost.

The excipient bill of materials is inexpensive. The value is in validated sterile production, regulatory approval, device integration, and dependable supply.

What licensing deals and litigation affect Seizalam?

Public commercial disclosures should be reviewed for any licensing, acquisition, distribution, or co-development agreement involving Seizalam’s sponsor, formulation technology, or delivery device. The available public product materials identify the FDA-approved product and its manufacturer, but do not establish a broad, publicly documented licensing network for the excipient system itself.[1,2]

A litigation assessment should distinguish among:

1. ANDA patent litigation involving listed patents;
2. commercial disputes over distribution or supply;
3. device patent litigation;
4. trade-secret claims involving manufacturing;
5. controlled-substance compliance disputes; and
6. product-liability litigation.

No litigation conclusion should be drawn from the existence of a patent application or a generic filing alone. The relevant record is the docket, asserted claims, court rulings, settlement terms, and any FDA approval outcome.

What is the revenue exposure and market opportunity?

Standalone Seizalam revenue is not generally disclosed in public filings as a separate line item. The addressable market includes:

• Emergency departments
• Ambulance services
• Hospitals
• Military and government agencies
• Correctional healthcare
• Neurology practices
• Emergency seizure-response kits

Revenue growth would depend on formulary adoption, stocking requirements, reimbursement, product availability, and the relative cost of intramuscular rescue compared with generic midazolam injection and noninvasive alternatives.

A premium product could justify higher pricing if it delivers measurable operational benefits:

• Faster administration
• Fewer preparation steps
• Lower dosing error risk
• Better field usability
• Longer storage stability
• Lower training burden
• Reduced dependence on intravenous access

The commercial threat is substitution by inexpensive generic injectable midazolam in hospitals and by intranasal or rectal rescue products outside institutional settings.

How strong is the Seizalam patent estate?

The estate appears structurally weaker than the estates of novel drugs or advanced delivery systems because:

• Midazolam is an old active ingredient;
• the labeled excipients are conventional;
• the dosage form is a standard sterile aqueous injection;
• competing midazolam injections are established; and
• product differentiation depends heavily on indication, presentation, and emergency-use positioning.

Potentially stronger assets would be narrow patents covering a validated formulation improvement, a prefilled syringe, an autoinjector, or a specific administration method. Their value would depend on remaining patent term, Orange Book listing, enforceability, and the commercial cost of design-around.

Key Takeaways

• Seizalam is a preservative-free, acidic midazolam hydrochloride injection for adult status epilepticus.
• Its excipient system is simple: sodium chloride, hydrochloric acid, sodium hydroxide, and water for injection.
• The acidic pH is necessary to maintain midazolam solubility and limits the feasibility of neutral-pH reformulation.
• The largest commercial opportunities involve prefilled syringes, autoinjectors, storage stability, and reduced injection-site irritation.
• Midazolam’s mature active-ingredient status creates meaningful generic-entry risk.
• Formulation claims based only on conventional excipient substitution may be weak unless linked to a demonstrated technical improvement.
• Publicly disclosed standalone Seizalam revenue is limited, so market assessment should focus on emergency-care adoption, institutional purchasing, and presentation-level differentiation.
• The FDA Orange Book and current patent records control the definitive analysis of listed patents, exclusivity, Paragraph IV exposure, and expiration dates.

FAQs About Seizalam Excipient and Commercial Strategy

What is the main excipient challenge in Seizalam formulation?

The central challenge is maintaining midazolam solubility in an injectable product while limiting the tolerability effects of an acidic solution.

Could Seizalam be reformulated at a neutral pH?

A neutral-pH formulation may improve local tolerability but creates precipitation and stability risks. It would require a new solubilization or stabilization strategy supported by comparative data.

Would a prefilled Seizalam syringe be patentable?

Potentially, if the product combines formulation, container, and delivery characteristics that produce a non-obvious stability, usability, or dosing advantage.

Is Seizalam protected by the midazolam molecule patent?

No. Midazolam is an established active ingredient. Any current protection would need to arise from formulation, method-of-use, device, packaging, or regulatory exclusivity rights.

What is the most credible generic threat to Seizalam?

The most credible threat is a lower-cost midazolam injection that matches the reference product’s strength, route, formulation characteristics, sterility, and labeling requirements, subject to any active FDA-listed patents or exclusivity.

References

1. U.S. Food and Drug Administration. (2024). Seizalam (midazolam) injection, prescribing information.
2. U.S. Food and Drug Administration. (2018). FDA approves first intramuscular formulation of midazolam for status epilepticus.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. Orange Book.